Jennifer M Nemeth

US Patent:

20190270826, Sep 5, 2019

Filed:

Mar 20, 2019

Appl. No.:

16/358894

Inventors:

- BEERSE, BE
Jennifer F. Nemeth - Spring House PA, US
Thai Dinh - San Diego CA, US
Rosa Maria Fernandes Cardoso - Spring House PA, US
Ricardo Marcos Attar - Spring House PA, US
Francois Gaudet - Spring House PA, US
Mark E. Salvati - Spring House PA, US

Assignee:

JANSSEN PHARMACEUTICA NV - BEERSE

International Classification:

C07K 16/30
A61K 39/395
C07K 16/46
A61K 45/06
C07K 16/28

Abstract:

Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multi specific antibodies against IL1RAP and CD3 described herein.

US Patent:

20170121420, May 4, 2017

Filed:

Nov 1, 2016

Appl. No.:

15/340149

Inventors:

- Beerse, BE
Jennifer F. Nemeth - Spring House PA, US
Thai Dinh - San Diego CA, US
Rosa Maria Fernandes Cardoso - Spring House PA, US
Darlene Pizutti - Spring House PA, US
Brandy Strake - Spring House PA, US
Jamie Fisher - Spring House PA, US
Ricardo Marcos Attar - Spring House PA, US
Francois Gaudet - Spring House PA, US
Mark E. Salvati - Spring House PA, US

Assignee:

Janssen Pharmaceutica NV - Beerse

International Classification:

C07K 16/30
A61K 39/395
A61K 45/06
C07K 16/28
C07K 16/46

Abstract:

Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multispecific antibodies against IL1RAP and CD3 described herein.